Drugs: From Discovery to Approval, 2nd edition

483 Pages·2008·6.66 MB·English

by  Rick Ng

DRUGS
From Discovery to Approval
Second Edition
RICK NG, PhD, MBA
A-Bio Pharma Pte Ltd, Singapore
A John Wiley & Sons, Ltd., Publication

DRUGS

DRUGS
From Discovery to Approval
Second Edition
RICK NG, PhD, MBA
A-Bio Pharma Pte Ltd, Singapore
A John Wiley & Sons, Ltd., Publication
Copyright © 2009 by John Wiley & Sons, Inc. All rights reserved.
Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global
Scientifi c, Technical, and Medical business with Blackwell Publishing.
Published by John Wiley & Sons, Inc., Hoboken, New Jersey.
Published simultaneously in Canada.
No part of this publication may be reproduced, stored in retrieval system, or transmitted in any
form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise,
except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without
either the prior written permission of the Publisher, or authorization through payment of the
appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive,
Danvers, MA 01923, [phone], fax [phone], or on the web at www.copyright.com.
Requests to the Publisher for permission should be addressed to the Permissions
Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, [phone],
fax [phone], or online at http://www.wiley.com/go/permission.
Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best
efforts in preparing this book, they make no representations or warranties with respect to the
accuracy or completeness of the contents of this book and specifi cally disclaim any implied
warranties of merchantability or fi tness for a particular purpose. No warranty may be created
or extended by sales representatives or written sales materials. The advice and strategies
contained herein may not be suitable for your situation. You should consult with a professional
where appropriate. Neither the publisher nor author shall be liable for any loss of profi t or any
other commercial damages, including but not limited to special, incidental, consequential, or
other damages.
For general information on our other products and services or for technical support, please
contact our Customer Care Department within the United States at [phone], outside the
United States at [phone] or fax [phone].
Wiley also publishes its books in a variety of electronic formats. Some content that appears in
print may not be available in electronic format. For information about Wiley products, visit our
web site at www.wiley.com.
Library of Congress Cataloging-in-Publication Data:
Ng, Rick.
Drugs : from discovery to approval / Rick Ng. – 2nd ed.
p. ; cm.
Includes bibliographical references and index.
ISBN 978-0-470-19510-9 (cloth)
1. Drug development. I. Title.
[DNLM: 1. Technology, Pharmaceutical. 2. Chemistry, Pharmaceutical.
3. Clinical Trials as Topic–methods. 4. Drug Approval–legislation & jurisprudence.
5. Drug Approval–methods. 6. Drug Design. QV 778 N576d 2009]
RM301.25.N5 2009
615'.19—dc22
2008035472
Printed in the United States of America.
10 9 8 7 6 5 4 3 2 1
To
Cherry, Shaun and Ashleigh

CONTENTS
PREFACE xiii
1 INTRODUCTION 1
1.1 Aim of This Book / 1
1.2 An Overview of the Drug Discovery and Development Process / 2
1.3 The Pharmaceutical Industry / 5
1.4 Economics of Drug Discovery and Development / 10
1.5 Trends in Drug Discovery and Development / 12
1.6 Case Study #1 / 14
1.7 Summary of Important Points / 16
1.8 Review Questions / 16
1.9 Brief Answers and Explanations / 16
1.10 Further Reading / 17
2 DRUG DISCOVERY: TARGETS AND RECEPTORS 19
2.1 Drug Discovery Processes / 20
2.2 Medical Needs / 21
2.3 Target Identifi cation / 23
2.4 Target Validation / 28
2.5 Drug Interactions with Targets or Receptors / 30
2.6 Enzymes / 34
vii